Long-term safety of omaveloxolone for Friedreich's ataxia
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at the long-term safety of omaveloxolone (BIIB141) for people with Friedreich's ataxia. You can join if you are just starting this medicine or have been taking it for less than a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Friedreich's ataxia (FA) through genetic testing.
- You must be 16 years old or older when you start taking omaveloxolone.
- If you are new to omaveloxolone, you can join when your doctor prescribes it as part of this study.
- If you are already taking omaveloxolone, you must have started it less than 12 months ago and not stopped for more than 60 days.
- You cannot have taken omaveloxolone without a prescription (off-label) or in a previous clinical trial.
- You cannot be in another blinded (hidden treatment) study at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called omaveloxolone (BIIB141) for children and teens with Friedreich’s Ataxia. It looks at how well the drug works and how safe it is over a longer time.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
This study follows people with Friedreich's ataxia (FA) who also have a heart condition called cardiomyopathy. By tracking how the disease progresses over time, researchers hope to better understand FA-related heart problems.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This study follows people with Friedreich's ataxia who took omaveloxolone during pregnancy or while breastfeeding, to check how the drug affected their health and their baby's health. It helps doctors understand the safety of this treatment for mothers and babies.
This study looks at whether omaveloxolone (a medication) can help improve swallowing problems in people with Friedreich's ataxia. If you have been taking omaveloxolone for at least 6 months, your data may help researchers understand if it helps with swallowing.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.